Clinical Trials · NCT02646189
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
- Phase
- Phase 1/Phase 2
- Recruitment status
- Completed
- Sponsor
- Replicor Inc.
- Enrollment
- 12
- Start date
- Aug 2011
- Locations
- 1 site, Bangladesh
- Primary endpoint
- Safety and tolerability of REP 2139-Ca + immunotherapy